Bris­tol-My­ers part­ners with Johns Hop­kins on Op­di­vo pact; A Valeant by any oth­er name…

Johns Hop­kins sci­en­tists will go to work study­ing Bris­tol-My­ers Squibb’s Op­di­vo and Yer­voy, look­ing for their weak points as the com­pa­ny looks to im­prove on these block­buster drugs. They’ll be study­ing pa­tient tu­mor sam­ples in four pri­ma­ry re­search ar­eas: char­ac­ter­i­za­tion of tu­mor anti­gens and tu­mor anti­gen-spe­cif­ic T-cells, mul­ti­fac­eted pro­fil­ing of the tu­mor mi­croen­vi­ron­ment, as­sess­ment of mi­cro­bio­me com­po­nents that mod­u­late sys­temic an­ti-tu­mor im­mu­ni­ty, and elu­ci­da­tion of nov­el tu­mor and im­muno-me­tab­o­lism fac­tors that mod­i­fy re­spon­sive­ness to im­munother­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER